Askpot
← Market research

Psychedelic Therapy (Psilocybin-Assisted Services) market analysis

The global psychedelic therapy market is in an early growth phase, with North America leading due to progressive regulatory changes and clinical adoption. Psilocybin-assisted therapy is gaining traction for treatment-resistant depression, PTSD, and end-of-life anxiety, but remains largely restricted to clinical trials or pilot programs outside select US states. Market expansion is closely tied to evolving legal frameworks, clinical evidence, and public acceptance.

CAGR

12.4

Challenges List
  • text

    Psychedelic substances remain Schedule I in most jurisdictions, creating legal ambiguity for providers and limiting insurance reimbursement and mainstream adoption.

    title

    Regulatory and Legal Uncertainty

  • text

    Shortage of trained facilitators and therapists, along with high operational costs, constrain scalability and access to care.

    title

    Clinical Infrastructure and Training Gaps

  • text

    Despite progress, negative perceptions and misinformation about psychedelics persist, particularly outside early-adopter regions.

    title

    Stigma and Public Perception

  • text

    Most psilocybin-assisted therapies are not covered by public or private insurance, resulting in high out-of-pocket costs for patients.

    title

    Reimbursement and Affordability

Current Market Size

1800000000

Drivers List
  • text

    State-level legalization in Oregon and Colorado, along with Australia's clinical rescheduling, have created the first legal commercial markets for psilocybin therapy, setting precedents for broader adoption.

    title

    Regulatory Liberalization in Key Markets

  • text

    Global prevalence of depression and anxiety disorders continues to rise, with the WHO estimating over 970 million people affected worldwide, fueling demand for novel, evidence-based interventions.

    title

    Rising Mental Health Burden and Unmet Need

  • text

    Phase II and III trials for psilocybin-assisted therapy have shown significant efficacy for treatment-resistant depression and PTSD, accelerating interest from providers and investors.

    title

    Expanding Clinical Evidence Base

  • text

    Surveys in the US and Europe indicate increasing openness among clinicians and patients to psychedelic therapies, especially as stigma declines and mainstream media coverage grows.

    title

    Growing Public and Professional Acceptance

Footnotes
line1

1) Market size includes legal and regulated psilocybin-assisted therapy services and clinical trial-related revenues; excludes illicit and unregulated use.

line2

2) Growth projections assume continued regulatory progress in North America and Oceania; downside scenario reflects potential policy reversals or slower adoption.

source

Askpot AI Analysis Report 2025

Headline

Psychedelic therapy: rapid North American growth, global expansion constrained by regulation

Introduction

The global psychedelic therapy market is in an early growth phase, with North America leading due to progressive regulatory changes and clinical adoption. Psilocybin-assisted therapy is gaining traction for treatment-resistant depression, PTSD, and end-of-life anxiety, but remains largely restricted to clinical trials or pilot programs outside select US states. Market expansion is closely tied to evolving legal frameworks, clinical evidence, and public acceptance.

Market

Psychedelic Therapy (Psilocybin-Assisted Services)

Regional Distribution
East Asia
Market Size

36000000

Share

2

Europe
Market Size

324000000

Share

18

Lat Am
Market Size

72000000

Share

4

North America
Market Size

1224000000

Share

68

Oceania
Market Size

126000000

Share

7

Southeast Asia
Market Size

18000000

Share

1

Regional Growth
East Asia
CAGR 2019 2024

2.1

CAGR 2024 2030 Base

3

CAGR 2024 2030 Downside

1

Drivers

Academic research in Japan and South Korea; rising mental health awareness.

Risks

Stringent drug laws; low public acceptance; minimal commercial pathways.

Europe
CAGR 2019 2024

7.8

CAGR 2024 2030 Base

9.1

CAGR 2024 2030 Downside

4

Drivers

Pilot programs in the UK, Netherlands, and Switzerland; increasing research funding; advocacy for mental health innovation.

Risks

Strict regulatory barriers; slow reimbursement adoption; fragmented policy landscape.

Lat Am
CAGR 2019 2024

5.5

CAGR 2024 2030 Base

6.2

CAGR 2024 2030 Downside

2.5

Drivers

Emerging wellness tourism; local research initiatives; cultural acceptance in select countries.

Risks

Weak regulatory frameworks; limited clinical infrastructure; affordability constraints.

North America
CAGR 2019 2024

15.1

CAGR 2024 2030 Base

13.2

CAGR 2024 2030 Downside

7.5

Drivers

Regulatory breakthroughs in Oregon and Colorado; rising clinical trial activity; growing mental health burden and demand for alternative therapies.

Risks

Federal legal uncertainty; insurance coverage gaps; public perception and stigma.

Oceania
CAGR 2019 2024

10.2

CAGR 2024 2030 Base

11

CAGR 2024 2030 Downside

6

Drivers

Australia’s rescheduling of psilocybin for clinical use; expanding clinical trial network; supportive mental health policy.

Risks

Limited practitioner base; high treatment costs; regulatory reversals.

Southeast Asia
CAGR 2019 2024

1.5

CAGR 2024 2030 Base

2

CAGR 2024 2030 Downside

0.5

Drivers

Niche wellness tourism; early-stage research collaborations.

Risks

Prohibitive legal status; limited clinical adoption; cultural barriers.